95 related articles for article (PubMed ID: 31678135)
1. Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2).
Masamrekh R; Filippova T; Haurychenka Y; Shcherbakov K; Veselovsky A; Strushkevich N; Shkel T; Gilep A; Usanov S; Shumyantseva V; Kuzikov A
Steroids; 2020 Feb; 154():108528. PubMed ID: 31678135
[TBL] [Abstract][Full Text] [Related]
2. The interactions of a number of steroid-metabolizing cytochromes P450 with abiraterone D4A metabolite: spectral analysis and molecular docking.
Masamrekh RA; Filippova TA; Haurychenka YI; Sherbakov KA; Veselovsky AV; Shumyantseva VV; Kuzikov AV
Steroids; 2020 Oct; 162():108693. PubMed ID: 32645328
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
[TBL] [Abstract][Full Text] [Related]
4. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
5. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
[TBL] [Abstract][Full Text] [Related]
6. [The interactions of abiraterone and its pharmacologically active metabolite D4A with cytochrome P450 2C9 (CYP2C9)].
Masamrekh RA; Kuzikov AV; Filippova TA; Sherbakov KA; Veselovsky AV; Shumyantseva VV
Biomed Khim; 2022 Jun; 68(3):201-211. PubMed ID: 35717584
[TBL] [Abstract][Full Text] [Related]
7. Interactions of galeterone and its 3-keto-Δ4 metabolite (D4G) with one of the key enzymes of corticosteroid biosynthesis - steroid 21-monooxygenase (CYP21A2).
Masamrekh RA; Filippova TA; Sherbakov KA; Veselovsky AV; Shumyantseva VV; Kuzikov AV
Fundam Clin Pharmacol; 2021 Apr; 35(2):423-431. PubMed ID: 33012006
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum to "Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2)" [Steroids 154 (2020) 108528].
Masamrekh R; Filippova T; Haurychenka Y; Shcherbakov K; Veselovsky A; Strushkevich N; Shkel T; Gilep A; Usanov S; Shumyantseva V; Kuzikov A
Steroids; 2020 Sep; 161():108674. PubMed ID: 32534271
[No Abstract] [Full Text] [Related]
9. Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry.
Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP
J Pharm Biomed Anal; 2018 May; 154():66-74. PubMed ID: 29533860
[TBL] [Abstract][Full Text] [Related]
10. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
[TBL] [Abstract][Full Text] [Related]
11. Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients.
Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121741. PubMed ID: 31421381
[TBL] [Abstract][Full Text] [Related]
12. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate.
Takahashi Y; Narita S; Shiota M; Miura M; Kagaya H; Kashima S; Yamamoto R; Nara T; Huang M; Numakura K; Saito M; Eto M; Habuchi T
Eur J Clin Pharmacol; 2023 Jan; 79(1):89-98. PubMed ID: 36378297
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation.
Mehralitabar H; Ghasemi AS; Gholizadeh J
Steroids; 2021 Mar; 167():108799. PubMed ID: 33465380
[TBL] [Abstract][Full Text] [Related]
14. Commentary on: "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy." Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Nature. 2016 May 25;533(7604):547-51.
Lee BH
Urol Oncol; 2017 Sep; 35(9):576. PubMed ID: 28789926
[TBL] [Abstract][Full Text] [Related]
15. An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.
van Nuland M; Rosing H; de Vries J; Ovaa H; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Nov; 1068-1069():119-124. PubMed ID: 29059586
[TBL] [Abstract][Full Text] [Related]
16. An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives.
Caron P; Turcotte V; Lévesque E; Guillemette C
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1104():249-255. PubMed ID: 30537624
[TBL] [Abstract][Full Text] [Related]
17. Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1).
Masamrekh R; Kuzikov A; Veselovsky A; Toropygin I; Shkel T; Strushkevich N; Gilep A; Usanov S; Archakov A; Shumyantseva V
J Inorg Biochem; 2018 Sep; 186():24-33. PubMed ID: 29807244
[TBL] [Abstract][Full Text] [Related]
18. A quick UPLC-MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in human plasma.
Weiss TLD; Furtado CM; Antunes MV; Gössling G; Schwartsmann G; Linden R; Verza SG
Biomed Chromatogr; 2020 Nov; 34(11):e4947. PubMed ID: 32652651
[TBL] [Abstract][Full Text] [Related]
19. In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions.
Masamrekh RA; Kuzikov AV; Haurychenka YI; Shcherbakov KA; Veselovsky AV; Filimonov DA; Dmitriev AV; Zavialova MG; Gilep AA; Shkel TV; Strushkevich NV; Usanov SA; Archakov AI; Shumyantseva VV
Fundam Clin Pharmacol; 2020 Feb; 34(1):120-130. PubMed ID: 31286572
[TBL] [Abstract][Full Text] [Related]
20. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
